Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
of 6

Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017

Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017SummaryGlobalData, the industry analysis specialist, has released its new report, 'Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017'. The report is an essential source of information and analysis on the global Polycystic Ovarian Syndrome (PCOS) market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.GlobalData estimated the Polycystic Ovarian Syndrome (PCOS) market to be worth $706m in 2009 and projects it to grow at a CAGR of 0.6% to reach $742m in 2017. The market is expected to decrease by 30.1% from $805m in 2011 to $563m in 2012. The decrease in the market will be due to the expiry of Letrozole's patent in the year 2011.The market will gain pace from 2013 and will grow to $742m in 2017. The slow growth rate is largely because of the under diagnosis of this syndrome. However, the market is driven by an increasing prevalence rate, diagnosis rate and treatment seeking rate. The rise in the prescription population will contribute to the growth of the PCOS market. Due to the presence of a large number of generic products and a weak pipeline, this market will not grow at a significant rate.Scope- The report provides information on the key drivers and challenges of the Polycystic Ovarian Syndrome (PCOS) market. Its Scope includes: - Annualized global PCOS market revenues data from 2001 to 2009, forecast for eight years to 2017. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as estrogen antagonists, female gamete inhibitor, insulin secretion inhibitor, HMG CoA inhibitor, Gastric and pancreatic lipase inhibitor and fats break down inhibitor.- Analysis of the current and future competition in the global PCOS market. Key market players covered are Merck KGaA, Catalysis SL and Amylin Pharma.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PCOS therapeutics marketReasons to buy- The report will enhance your decision making capability. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global PCOS therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global PCOS therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global PCOS therapeutics market landscape' ' Identify, understand and capitalize.
Published on: Mar 4, 2016
Source: www.slideshare.net


Transcripts - Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017

  • 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Polycystic Ovarian Syndrome - Pipeline Assessment and MarketForecasts to 2017Published on September 2010 Report SummaryPolycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017SummaryGlobalData, the industry analysis specialist, has released its new report, Polycystic Ovarian Syndrome - Pipeline Assessment andMarket Forecasts to 2017. The report is an essential source of information and analysis on the global Polycystic Ovarian Syndrome(PCOS) market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights onthe prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the currentmarket leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. Thisreport is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysisby GlobalDatas team of industry experts.GlobalData estimated the Polycystic Ovarian Syndrome (PCOS) market to be worth $706m in 2009 and projects it to grow at a CAGRof 0.6% to reach $742m in 2017. The market is expected to decrease by 30.1% from $805m in 2011 to $563m in 2012. The decreasein the market will be due to the expiry of Letrozoles patent in the year 2011.The market will gain pace from 2013 and will grow to$742m in 2017. The slow growth rate is largely because of the under diagnosis of this syndrome. However, the market is driven by anincreasing prevalence rate, diagnosis rate and treatment seeking rate. The rise in the prescription population will contribute to thegrowth of the PCOS market. Due to the presence of a large number of generic products and a weak pipeline, this market will not growat a significant rate.Scope- The report provides information on the key drivers and challenges of the Polycystic Ovarian Syndrome (PCOS) market. Its Scopeincludes:- Annualized global PCOS market revenues data from 2001 to 2009, forecast for eight years to 2017.- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends.Pipeline candidates fall under major therapeutic classes such as estrogen antagonists, female gamete inhibitor, insulin secretioninhibitor, HMG CoA inhibitor, Gastric and pancreatic lipase inhibitor and fats break down inhibitor.- Analysis of the current and future competition in the global PCOS market. Key market players covered are Merck KGaA, CatalysisSL and Amylin Pharma.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide aqualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for thePCOS therapeutics marketReasons to buy- The report will enhance your decision making capability. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and byPolycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 1/6
  • 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global PCOS therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely toimpact the global PCOS therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance ofvarious competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitiveadvantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunitiesfor consolidations, investments and strategic partnerships.- Whats the next big thing in the global PCOS therapeutics market landscape Identify, understand and capitalize. Table of Content1 Table of contents 31.1 List of Tables 51.2 List of Figures 52 Polycystic Ovarian Syndrome: Introduction 62.1 GlobalData Pipeline Report Guidance 63 Polycystic Ovarian Syndrome: Market Characterization 73.1 Market Overview 73.2 Polycystic Ovarian Syndrome Market Size 73.3 Polycystic Ovarian Syndrome Market Forecast and CAGR 83.4 Drivers and Barriers for the Polycystic Ovarian Syndrome Market 93.4.1 Drivers for Polycystic Ovarian Syndrome Market 93.4.2 Barriers for Polycystic Ovarian Syndrome Market 103.5 Opportunity and Unmet Need 113.6 Key Takeaway 124 Polycystic Ovarian Syndrome Market: Competitive Assessment 134.1 Overview 134.2 Strategic Competitor Assessment 134.3 Product Profile for the Major Marketed Products in the Polycystic Ovarian Syndrome Market 144.3.1 Clomid 144.4 Product Profile for Major Off-Label Drugs for Polycystic Ovarian Syndrome 164.4.1 Metformin 164.4.2 Letrozole 174.4.3 Flutamide 184.5 Key Takeaway 205 Polycystic Ovarian Syndrome: Pipeline Assessment 215.1 Overview 215.2 Strategic Pipeline Assessment 215.2.1 Technology Trends Analytic Framework 215.3 Molecule Profile for Major Pipeline Molecules under Clinical Development 225.3.1 Metformin + Exenatide 225.3.2 Follitropin alfa liquid formulation 235.3.3 Human Gonadotropin Hormone 23Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 2/6
  • 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!5.3.4 Simvastatin 235.3.5 Orlistat 245.3.6 Clomiphene citrate + raloxifene 255.3.7 Oral DCI 255.3.8 Sibutramine + Loestrin (ethinyl estradiol) 255.3.9 Leuprolide acetate + Spironolactone 265.3.10 Oral Cinnamon Extract 265.3.11 Oral Contraceptives 265.3.12 Dietary Supplement: Diamel 275.3.13 Dietary Supplement: Flaxeed 275.3.14 Dietary Supplement: Alpha Lipoic Acid 275.3.15 Dietary Supplement: Vitamin D 285.4 Polycystic Ovarian Syndrome Clinical Pipeline by Mechanism of Action 295.5 Polycystic Ovarian Syndrome Pipeline by Phase of Clinical Development 305.5.1 Polycystic Ovarian Syndrome Phase III Clinical Pipeline 305.5.2 Polycystic Ovarian Syndrome Phase II Clinical Pipeline 315.5.3 Polycystic Ovarian Syndrome Phase I Clinical Pipeline 315.6 Key Takeaway 316 Polycystic Ovarian Syndrome: Implications for the Future Market Competition 327 Polycystic Ovarian Syndrome: Future Players in Polycystic Ovarian Syndrome Market 337.1 Merck KGaA 337.1.1 Company Overview 337.1.2 Business Description 337.1.3 Female Sexual Dysfunction Portfolio 347.2 Catalysis SL 347.2.1 Company overview 347.2.2 Female Sexual Dysfunction Portfolio 348 Polycystic Ovarian Syndrome: Appendix 358.1 Definitions 358.2 Abbreviations 358.3 Scope of Pipeline Research 358.4 Research Methodology 368.4.1 Coverage 368.4.2 Secondary Research 368.4.3 Forecasting 368.4.4 Primary Research 398.4.5 Expert Panel Validation 398.5 Contact Us 398.6 Disclaimer 398.7 Sources 401.1 List of TablesTable 1: Polycystic Ovarian Syndrome Market, Global, Revenue ($m), 20012009 8Table 2: Polycystic Ovarian Syndrome Market, Global, Forecast Revenue ($m), 20092017 9Table 3: Major Marketed Products Analysis in the Polycystic Ovarian Syndrome Market, 2010 19Table 4: Polycystic Ovarian Syndrome Phase III Clinical Pipeline, 2010 30Table 5: Polycystic Ovarian Syndrome Phase II Clinical Pipeline, 2010 31Table 6: Polycystic Ovarian Syndrome - Phase I Clinical Pipeline, 2010 31Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 3/6
  • 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Table 7: Merck KGaA Female Sexual Dysfunction Pipeline Products, 2010 34Table 8: Catalysis SL Female Sexual Dysfunction Pipeline Products, 2010 341.2 List of FiguresFigure 1: Polycystic Ovarian Syndrome Market, Global, Revenues ($m), 20012009 8Figure 2: Polycystic Ovarian Syndrome Market, Global, Forecast Revenues ($m), 20092017 9Figure 3: Opportunity and Unmet Need in the Polycystic Ovarian Syndrome Market, 2010 11Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Polycystic Ovarian Syndrome, 2010 14Figure 5: Technology Trends Analytics Framework of the Polycystic Ovarian Syndrome Pipeline, 2010 21Figure 6: Technology Trends Analytic Framework of the Polycystic Ovarian Syndrome Pipeline Description, 2010 22Figure 7: Polycystic Ovarian Syndrome Clinical Pipeline by Mechanism of Action, 2010 29Figure 8: Polycystic Ovarian Syndrome Clinical Pipeline by Phase of Development, 2010 30Figure 9: Polycystic Ovarian Syndrome Implications for Future Market Competition, 2010 32Figure 10: GlobalData Market Forecasting Model 38Companies mentionedMerck KGaACatalysis SLPolycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 4/6
  • 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 000.00 Quantity: _____ Site License--USD 4 000.00 Quantity: _____ Corporate License--USD 6 000.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 5/6
  • 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 6/6

Related Documents